Ilana Schlam, Breast medical oncologist at Dana-Farber Cancer Institute, shared a post on X:
”Happy to share our review on ctDNA in early breast cancer. We discuss current evidence, clinical applications, challenges, and future directions.”
Title: Circulating Tumor DNA in Early Breast Cancer
Authors: Ilana Schlam, Sara M. Tolaney, Nancy U. Lin, Heather Parsons, Stefania

WSG TP-II Trial: Excellent 5-Year Survival After De-Escalated Neoadjuvant Therapy In HR+/HER2+ Early Breast Cancer
